Cytomorphological features of ALK-positive lung adenocarcinomas: Psammoma bodies and signet ring cells

Cancer Cytopathology

Volumn 123, Issue 3, 2015, Pages 162-170

  Pareja, Fresia ^a   Crapanzano, John P ^a   Mansukhani, Mahesh M ^a   Bulman, William A ^a,b   Saqi, Anjali ^a  

^a NewYork Presbyterian Hospital   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

anaplastic lymphoma kinase (ALK); cytology; epidermal growth factor receptor (EGFR); fine needle aspiration; lung adenocarcinoma; micropapillary; mucinous; papillary; psammoma bodies; signet ring cells

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE;

ADULT; AGED; ALK GENE; ARTICLE; CANCER CELL; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPATHOLOGY; EGFR GENE; FEMALE; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; MALE; ONCOGENE K RAS; PRIORITY JOURNAL; PSAMMOMA BODY; RETROSPECTIVE STUDY; SIGNET RING CELL; SMOKING; VERY ELDERLY; WILD TYPE; ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ANIMAL; CANCER STAGING; CARCINOMA, PAPILLARY; CARCINOMA, SIGNET RING CELL; FOLLOW UP; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CARCINOMA, PAPILLARY; CARCINOMA, SIGNET RING CELL; FEMALE; FOLLOW-UP STUDIES; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES;

EID: 84929133686     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21507     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, et al., Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96.
2. Devesa SS, Bray F, Vizcaino AP, Parkin DM,. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005; 117: 294-299.
3. Soda M, Choi YL, Enomoto M, et al., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448: 561-566.
4. Rikova K, Guo A, Zeng Q, et al., Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131: 1190-1203.
5. Djalalov S, Beca J, Hoch JS, et al., Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol. 2014; 32: 1012-1019.
6. Kwak EL, Bang YJ, Camidge DR, et al., Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693-1703.
7. Shaw AT, Kim DW, Nakagawa K, et al., Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368: 2385-2394.
8. Yoshida A, Tsuta K, Nakamura H, et al., Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol. 2011; 35: 1226-1234.
9. Nishino M, Klepeis VE, Yeap BY, et al., Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Mod Pathol. 2012; 25: 1462-1472.
10. Kadota K, Suzuki K, Kachala SS, et al., A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Mod Pathol. 2012; 25: 1117-1127.
11. Inamura K, Takeuchi K, Togashi Y, et al., EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008; 3: 13-17.
12. Jokoji R, Yamasaki T, Minami S, et al., Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J Clin Pathol. 2010; 63: 1066-1070.
13. Inamura K, Takeuchi K, Togashi Y, et al., EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009; 22: 508-515.
14. Rodig SJ, Mino-Kenudson M, Dacic S, et al., Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009; 15: 5216-5223.
15. Kim H, Jang SJ, Chung DH, et al., A comprehensive comparative analysis of the histomorphological features of ALK-rearranged lung adenocarcinoma based on driver oncogene mutations: frequent expression of epithelial-mesenchymal transition markers than other genotype. PLoS One. 2013; 8: e76999.
16. Toll AD, Maleki Z,. Cytomorphology of non-small cell lung carcinoma with anaplastic lymphoma kinase gene rearrangement [published online ahead of print April 10, 2014]. Diagn Cytopathol. doi: 10.1002/dc.23160.
17. Li Z, Dacic S, Pantanowitz L, Khalbuss WE, Nikiforova MN, Monaco SE,. Correlation of cytomorphology and molecular findings in EGFR+, KRAS+, and ALK+ lung carcinomas. Am J Clin Pathol. 2014; 141: 420-428.
18. Travis WD, Brambilla E, Noguchi M, et al., International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011; 6: 244-285.
19. Thunnissen E, Beasley MB, Borczuk AC, et al., Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol. 2012; 25: 1574-1583.
20. Rudomina DE, Lin O, Moreira AL,. Cytologic diagnosis of pulmonary adenocarcinoma with micropapillary pattern: does it correlate with the histologic findings? Diagn Cytopathol. 2009; 37: 333-339.
21. Rodriguez EF, Monaco SE, Dacic S,. Cytologic subtyping of lung adenocarcinoma by using the proposed International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) adenocarcinoma classification. Cancer (Cancer Cytopathol). 2013; 121: 629-637.
22. Miyoshi I, Kubota T, Saito T, et al., Psammoma bodies in lung cancer. Intern Med. 2006; 45: 335-336.
23. Kuroda N, Hamaguchi N, Takeuchi E, Ohara M, Hirouchi T, Mizuno K,. Lung adenocarcinoma with a micropapillary pattern: a clinicopathological study of 25 cases. APMIS. 2006; 114: 381-385.
24. Sica G, Yoshizawa A, Sima CS, et al., A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol. 2010; 34: 1155-1162.
25. Lindeman NI, Cagle PT, Beasley MB, et al., Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013; 137: 828-860.